Alm. Brand A/S
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S share buy-back program
Transactions during 24 March 2025 – 28 March 2025
On 5 March 2025, Alm. Brand A/S announced a share buy-back program of up to DKK 835.2 million, as described in company announcement no. 21/2025.
The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.
The following transactions were made under the share buy-back program during week number 13:
| Number of shares bought | Average purchase price | Amount (DKK) | |
| Accumulated, last announcement | 2,650,000 | 16.47 | 43,566,600 |
| 24 March 2025 | 170,000 | 16.54 | 2,811,800 |
| 25 March 2025 | 190,000 | 16.72 | 3,176,800 |
| 26 March 2025 | 170,000 | 16.84 | 2,862,800 |
| 27 March 2025 | 170,000 | 16.87 | 2,867,900 |
| 28 March 2025 | 180,000 | 16.74 | 3,013,200 |
| Total, week number 13 | 880,000 | 16.74 | 14,732,500 |
| Accumulated under the program | 3,530,000 | 16.54 | 58,299,100 |
With the transactions stated above Alm. Brand A/S holds a total of 96,949,230 own shares corresponding to 6.29 % of the total number of outstanding shares.
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Head of IR, Rating and ESG reporting
Mads Thinggaard
Mobile no. +45 2025 5469
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
nCino, Inc.1.4.2025 22:06:00 CEST | Press release
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results
nCino, Inc.1.4.2025 22:05:00 CEST | Press release
nCino Announces Stock Repurchase Program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom